Use of protein SATB2 as a marker for colorectal cancer

Details Use of protein SATB2 as a marker for colorectal cancer Use of protein SATB2 as a marker for colorectal cancer

2007-06-04

2011-11-29

Goddard, Laura B (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S007100

Reexamination Certificate

active

08067190

ABSTRACT:
The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.

REFERENCES:
patent: 2003/0129207 (2003-07-01), Meagher et al.
patent: 2008/0311567 (2008-12-01), Bruckl et al.
patent: 2009/0270267 (2009-10-01), Akiyama et al.
patent: 1862803 (2007-12-01), None
patent: 2435882 (2007-09-01), None
patent: WO 00/40752 (2000-07-01), None
patent: WO 03/022126 (2003-03-01), None
patent: WO-03/022126 (2003-03-01), None
patent: WO-2005/107396 (2005-11-01), None
patent: WO-2006/015742 (2006-02-01), None
Patani et al (Cancer Cell International, 2009, 9:18; internet pp. 1-10).
Chung et al (EMBO Reports; online publication Sep. 2010; p. 1-7).
Soong et al (Clinical Cancer Research, 2001, 7:3423-3429).
Wang et al (J of Pathology, 2009, 219:114-122).
Giribaldi et al (J Molecular Diagnostics, 2006, 8:105-112).
Cheng et al (Clinica Chimica Acta, 2010, 411:234-241).
Kummar et al (British J of Cancer, 2002, 86:1884-1887).
Pasche et al., Best Practice & Research. Clinical Gastroenterology, vol. 16, No. 2, Apr. 2002, pp. 331-345, XP002447570.
Agaton et al., “Genome-based proteomics”, Electrophoresis 2004, vol. 25, pp. 1280-1288.
Andersson et al., “Analysis of Protein Expression in Cell Microarrays: A Tool for Antibody-based Proteomics”, Journal of Histochemistry & Cytochemistry, vol. 54(12), pp. 1413-1423, 2006.
Bode et al., “Transcriptional Augmentation: Modulation of Gene Expression by Scaffold/Matrix Attached Regions (S/MAR Elements)”, National Center for Biotechnological Research, 1999.
Britanova et al., “Novel transcription factor Satb2 interacts with matrix attachment region DNA elements in a tissue-specific manner and demonstrates cell-type-dependent expression in the developing mouse CNS”, European Journal of Neuroscience, vol. 21, pp. 658-668, 2005.
Van Buggenhout et al., “The del(2)(q32.2q33) deletion syndrome defined by clinical and molecular characterization of four patients”, European Journal of Medical Genetics, vol. 48, pp. 276-289, 2005.
Dickinson et al., “A Tissue-Specific MAR/SAR DNA-Binding Protein with Unusual Binding Site Recognition”, Cell, vol. 70, pp. 631-645, Aug. 21, 1992.
Dobreva et al., “SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin μ gene expression”, Genes & Development, 2003, vol. 17, pp. 3048-3061.
Fitzpatrick et al., “Identification of SATB2 as the cleft palate gene on 2q32-q33”, Human Molecular Genetics, vol. 12, No. 19, 2003, pp. 2491-2501.
Groene et al., “Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III”, Int. J. Cancer; vol. 119, pp. 1829-1836, 2006.
Kampf et al., “Antibody-Based Tissue Profiling As a Tool for Clinical Proteomics”, The Journal of Translational Molecular Medicine, vol. 1, Nos. 3-4, ISSN 1542-6416, pp. 285-299, 2004.
Kikuno et al., “Prediction of the Coding Sequences of Unidentified Human Genes. XIV. The Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins in vitro”, DNA Research, vol. 6, pp. 197-205, 1999.
Lindskog et al., “Selection of protein epitopes for antibody production”, BioTechniques 38, pp. 723-727, May 2005.
Salahshor et al., “Differential gene expression profile reveals deregulation of pregnancy specific βl glycoprotein 9 early during colorectal carcinogenesis”, BMC Cancer, 2005, vol. 5 No. 66, pp. 1-14.
Uhlen et al., “Antibody-based Proteomics for Human Tissue Profiling”, Molecular & Cellular Proteomics 4.4, 2005, pp. 384-393.
Uhlen et al., “A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics”, Molecular & Cellular Proteomics 4.12, 2005, pp. 1920-1932.
Yasui et al., “SATB1 targets chromatin remodelling to regulate genes over long distances”, Nature, vol. 419, Oct. 10, 2002, pp. 641-645.
AU Office Action, Appl. No. 2007256391, Jan. 20, 2011, pp. 1-4.
EPO Office Action, Appl. No. 07725799.6, Mar. 1, 2010, pp. 1-4.
EPO Search Report, Appl. No. 10158956.2, Jun. 25, 2010, pp. 1-8.
Tot, T., “Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma,” European Journal of Cancer, 2002, vol. 38, pp. 758-763.
Extended European Search Report dated Mar. 10, 2009, for Application No. 08165897.3.
PCT International Preliminary Report on Patentability and Written Opinion of the International Searching Authority,dated Apr. 12, 2011, for Application No. PCT/EP2009/062956.
Rockberg et al., “Epitope mapping of antibodies using bacterial surface display”, Nature Methods, Dec. 2008, vol. 5, No. 12, pp. 1039-1045.

Affiliated with

Also associated with

Rating

Use of protein SATB2 as a marker for colorectal cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of protein SATB2 as a marker for colorectal cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of protein SATB2 as a marker for colorectal cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4302490